Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01233648 · ClinicalTrials.gov registry record · Phase 4
Resync-AF (Rate vs Rhythm Control in AF Patients With CRT-D)
A Phase 4 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 4
- Development phase
- 52
- Enrollment target
NCT01233648 is a Phase 4 study that has completed, run by University of Pittsburgh. The registered enrollment target is 52 participants.
The verdict
NCT01233648, a Phase 4 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 52 participants
- Enrollment target
Study Summary
This study is being done to find out if controlling rate or controlling rhythm is better for heart failure patients who also have AF. Patients with AF who are receiving a CRT-D device and AV node ablation as part of their clinical care will be followed for one year. One group will have their heart rate controlled by the ICD and AVN ablation alone and the second group will be treated with the ICD, AVN ablation and standard medical therapies to restore the heart's normal rhythm. The study doctors will compare the information collected from all of the subjects in this study to see if treating rate or treating rhythm is better in patients with heart failure and AF, resulting in a better quality of life.
Interventions
- OTHER rate control via CRT-D and AVN ablation
- OTHER rhythm control via pharmacologic, electrical or ablative therapies
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2006-06 |
| Est. Completion | 2015-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01233648
The ClinicalTrials.gov registry entry for NCT01233648 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which rate control via CRT-D and AVN ablation is the first listed.
NCT01233648 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01233648 about?
NCT01233648 is a clinical study titled "Resync-AF (Rate vs Rhythm Control in AF Patients With CRT-D)". This study is being done to find out if controlling rate or controlling rhythm is better for heart failure patients who also have AF. Patients with AF who are receiving a CRT-D device and AV node ablation as part of their clinical care will be followed for one year. One group will have their heart r...
What is the current status of trial NCT01233648?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 52 participants. The study started on 2006-06. Estimated completion is 2015-11.
What interventions are being tested in trial NCT01233648?
The interventions under investigation include: rate control via CRT-D and AVN ablation (OTHER), rhythm control via pharmacologic, electrical or ablative therapies (OTHER).
Who is sponsoring clinical trial NCT01233648?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.